Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial.

Abstract

A double-blind controlled trial was carried out to compare the effects of chenodeoxycholic acid (CDCA), ursodeoxycholic acid (UDCA), and placebo on cholesterol and triglyceride levels in patients with endogenous hypertriglyceridemias. The dose of both bile acids was four 150-mg capsules day. Total serum cholesterol levels did not show appreciable changes with any of the treatments. HDL cholesterol was significantly increased after CDCA but not after UDCA or placebo. CDCA feeding was associated with a significant decrease in serum triglyceride levels, whereas the other treatments failed to show an effect. It is concluded that UDCA does not affect serum lipid levels, whereas CDCA lowers serum triglycerides and may be useful in the treatment of endogenous hypertriglyceridemia.

• Authors: N Carulli, M Ponz de Leon, M Podda, M Zuin, A Strata, G Frigerio, A Digrisolo
• Journal: Journal of clinical pharmacology (J Clin Pharmacol) Vol. 21 Issue 10 Pg. 436-42 (Oct 1981) ISSN: 0091-2700 [Print] England
• PMID: 7031100 (Publication Type: Clinical Trial, Comparative Study, Journal Article)

Chemical References

• Triglycerides
• Deoxycholic Acid
• Chenodeoxycholic Acid
• Ursodeoxycholic Acid
• Cholesterol

Topics

• Adult
• Chenodeoxycholic Acid (therapeutic use)
• Cholesterol (blood)
• Clinical Trials as Topic
• Deoxycholic Acid (analogs & derivatives)
• Double-Blind Method
• Female
• Humans
• Hyperlipidemias (drug therapy)
• Male
• Triglycerides (blood)
• Ursodeoxycholic Acid (therapeutic use)